Trials / Completed
CompletedNCT04897126
Efficacy and Safety of Shexiang Baoxin Pill in Patients With Ischemia With Non-Obstructive Coronary Artery
Efficacy and Safety of Shexiang Baoxin Pill in Patients With Ischemia With Non-Obstructive Coronary Artery: A Phase 4, Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 240 (actual)
- Sponsor
- Shanghai Hutchison Pharmaceuticals Limited · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a multicenter, randomized, double-blind, placebo-controlled clinical trial. Patients were treated with the trial drug or placebo in a 1:1 ratio. The control group was treated with placebo 4 pills / day, 3 times / day on the basis of conventional treatment until the end of follow-up, while the experimental group was treated with MUSK Pill 4 pills / day, 3 times / day on the basis of conventional treatment until the end of follow-up.
Conditions
- Ischemia With Non-Obstructive Coronary Artery
- Angina Pectoris
- Coronary Heart Disease
- X Syndrome, Angina
Interventions
| Type | Name | Description |
|---|---|---|
| RADIATION | Shexiang Baoxin pill（MUSKARDIA） | On the basis of routine treatment, MUSK Pills were added to 4 capsules / day, 3 times per day until the end of follow-up. |
| RADIATION | Placebo | On the basis of routine treatment, Placebo were added to 4 capsules / day, 3 times per day until the end of follow-up. |
Timeline
- Start date
- 2021-05-11
- Primary completion
- 2023-07-04
- Completion
- 2023-10-25
- First posted
- 2021-05-21
- Last updated
- 2024-04-23
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04897126. Inclusion in this directory is not an endorsement.